IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
Results showed 15.4% of patients experienced treatment-related serious adverse events with IMFINZI plus chemotherapy versus 17.3% with chemotherapy alone.
- Results showed 15.4% of patients experienced treatment-related serious adverse events with IMFINZI plus chemotherapy versus 17.3% with chemotherapy alone.
- Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
- IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
- The primary endpoint is overall survival and key secondary endpoints included progression-free survival, objective response rate and safety.